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CTCF genetic alterations in endometrial carcinoma
are pro-tumorigenic
AD Marshall1,2, CG Bailey1,2, K Champ1,2, M Vellozzi1,2, P O’Young1,2, C Metierre1,2, Y Feng1,2, A Thoeng1,2, AM Richards3, U Schmitz1,2,
M Biro4, R Jayasinghe5,6, L Ding5,6, L Anderson2,7, ER Mardis5,6 and JEJ Rasko1,2,8
CTCF is a haploinsufficient tumour suppressor gene with diverse normal functions in genome structure and gene regulation.
However the mechanism by which CTCF haploinsufficiency contributes to cancer development is not well understood. CTCF is
frequently mutated in endometrial cancer. Here we show that most CTCF mutations effectively result in CTCF haploinsufficiency
through nonsense-mediated decay of mutant transcripts, or loss-of-function missense mutation. Conversely, we identified a
recurrent CTCF mutation K365T, which alters a DNA binding residue, and acts as a gain-of-function mutation enhancing cell
survival. CTCF genetic deletion occurs predominantly in poor prognosis serous subtype tumours, and this genetic deletion is
associated with poor overall survival. In addition, we have shown that CTCF haploinsufficiency also occurs in poor prognosis
endometrial clear cell carcinomas and has some association with endometrial cancer relapse and metastasis. Using shRNA targeting
CTCF to recapitulate CTCF haploinsufficiency, we have identified a novel role for CTCF in the regulation of cellular polarity of
endometrial glandular epithelium. Overall, we have identified two novel pro-tumorigenic roles (promoting cell survival and altering
cell polarity) for genetic alterations of CTCF in endometrial cancer.
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INTRODUCTION
Uterine malignancies represent the most prevalent gynaecological
cancers in the developed world. These tumours are becoming an
increasing health burden due to associations with increased body
mass index, nulliparity and increased life expectancy.1,2 The
majority (95%) of these tumours are endometrial carcinomas that
originate from the endometrial glandular epithelium. The remain-
ing 5% have a mesenchymal component such as endometrial
stromal sarcoma or are mixed epithelial and stromal tumours such
as adenosarcomas and carcinosarcomas.3,4 Within endometrial
carcinoma, the majority of tumours (~80%) are endometrioid
adenocarcinomas, which are generally hormone-responsive, are
typified by PTEN deletion, and carry a good prognosis. The next
most common subtypes are serous carcinoma (5–10%) and clear
cell carcinoma (o5%), which are generally non-hormone-
responsive and associated with a poorer prognosis. Additionally,
serous tumours often carry TP53 mutations.3–5 Rarer subtypes
include mucinous carcinoma, squamous cell carcinoma, undiffer-
entiated carcinoma, and mixed carcinoma which by definition
contains at least two histological cell types such as endometrioid
and serous carcinoma.3
Cancer genome sequencing studies focusing on large patient
cohorts of specific cancers are revealing the molecular genetic
landscapes of tumours. Recently, we showed that endometrioid
tumours had frequent mutations in PTEN, CTNNB1, PIK3CA, ARID1A,
ARID5B and KRAS.5 We also discovered that CTCF, encoding the
chromatin organising protein CTCF is mutated in about one
quarter of endometrial carcinoma.5 This was verified in indepen-
dent endometrial cancer cohorts.6,7 Importantly, of 127 signifi-
cantly mutated genes (SMGs) in 12 different cancers, CTCF was
identified as an SMG in endometrial cancer.8 CTCF mutations have
also been identified at similar or lower frequencies in other
tumour types including breast and prostate cancer, Wilms’ tumour
and leukaemia.9–12 A CTCF mutation has been identified at relapse
in acute lymphoblastic leukaemia11 indicating a potential role for
CTCF mutation in tumour relapse. Specific mutations in the zinc
finger (ZF) domain of CTCF result in reduced or abrogated CTCF
DNA binding activity at certain cognate target sites, but not
others.10
CTCF is an 11-ZF DNA binding protein that has been named the
'master weaver of the genome'13 due to its diverse functions in
the regulation of chromatin structure and function including:
inter- and intra- chromosomal interactions, gene regulation,
nucleosome positioning, gene insulation, genetic imprinting,
demarcation of lamina associated domains, X-chromosome
inactivation, alternative splicing and telomere elongation
(reviewed in Marshall et al.14). We first showed that CTCF can
repress cell growth and colony formation suggesting a tumour
suppressor function for CTCF.15 In addition, CTCF expression also
confers a protective effect against apoptosis in various cell
lines.16,17 CTCF has been shown to modulate the expression of
various cancer-associated gene loci including notable examples:
CMYC,18 IGF2,19 TP53,20 TERT21 and INK4/ARF.22 Loss of CTCF
binding via aberrant DNA methylation of critical control regions
can induce epigenetic silencing of tumour suppressor loci or lead
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to activation of oncogenes.23,24 Ctcf heterozygous mice are
prone to tumour development in various tissues including the
uterus.25 This verifies CTCF’s role as a haploinsufficient tumour
suppressor gene.
Here we show that CTCF mutations identified in primary human
endometrial carcinoma predominantly showed loss-of-function
phenotypes due to nonsense-mediated decay of mutant tran-
scripts or abrogation of functional activity. In addition, we also
identified a recurrent mutation in CTCF, K365T, which showed a
gain-of-function phenotype promoting increased cell survival
following apoptotic insult. To recapitulate CTCF haploinsufficiency
in CTCF wild-type (WT) cells we used shRNA knockdown of CTCF.
We show that reduced CTCF expression reduces the proportion of
spheroids showing luminal localisation of apical polarity markers
F-Actin and ZO-1 in 3D endometrial spheroid culture, indicating
CTCF plays a role in regulating the normal structure of
endometrial glands. Furthermore, our copy number variation
analysis of primary human endometrial cancers demonstrates that
CTCF deletion occurs more commonly in tumours with a
propensity for relapse or metastasis, and in tumours with clear
cell histology. These findings provide further evidence that
genetic lesions in CTCF promote endometrial carcinogenesis.
RESULTS
CTCF is mutated in endometrioid adenocarcinomas and related
cell lines
We and others have identified over 200 somatic CTCF mutations
occurring in primary human endometrial carcinoma samples5–7,26
(Figure 1a and Supplementary Table 1). The majority (71%) are
inactivating mutations resulting from frameshift (45%), nonsense
(20%) and splice site mutations (6%). The remaining mutations
(29%) are missense mutations with the majority (43/60, 72%,
Po0.001 Fisher’s exact test) occurring within the 11-ZF DNA
binding domain of CTCF. All of the recurrently mutated residues in
CTCF (S345, K352, K365, G375, R377, P378, A387, and R567) occur
within the ZF domain and are predominantly clustered within ZF 4
(Figure 1b, P= 0.0041, Fisher’s exact test). As CTCF is a significantly
mutated gene in endometrial cancer, we sequenced CTCF in five
endometrial cancer cell lines and identified four mutations
(Figures 1a and c). These included two recurrent CTCF mutations:
T204fs*26 in Ishikawa and R342H in both HEC1A and HEC1B and
two novel mutations: G19* in HEC1B and R278C in RL95-2.
Interestingly HEC1B, which is a sub-strain of HEC1A isolated from a
patient with grade II endometrial cancer,27 has acquired an
additional somatic mutation in CTCF, G19*. Only the KLE
endometrial cancer cell line did not contain any CTCF mutations.
KLE has previously been shown to be diploid for Ch1628 and does
not contain focal deletions within Ch16q22.1.29 The location of
missense mutations within the ZF domains of CTCF is shown in
Figure 1d and includes mutations affecting zinc ion binding, DNA
binding and non-binding residues.
Within our published patient cohort CTCF was sequenced in 172
endometrioid adenocarcinomas and 60 serous carcinomas.5 In all,
16 missense and 25 inactivating mutations (including 17 nonsense
and 8 frameshift mutations) were identified (Supplementary
Table 2). All somatic CTCF mutations were identified within the
endometrioid subtype (Fisher’s exact test Po0.001; Figure 2a). We
determined the proportion of mutant to wild-type alleles in
tumour samples following DNA and RNA sequencing. In tumour
DNA, there was a similar ratio of mutant to wild-type alleles for
missense mutations and inactivating mutations (37.6 ± 3.2% and
32.8 ± 2.3%, respectively, mean± s.e.m) consistent with monoalle-
lic mutation of CTCF (Figure 2b). The proportion of expressed
alleles with missense mutations was 63.1 ± 6.3% and with
inactivating mutations was 7.7 ± 3.2% (mean +/- s.e.m.), indicating
that most nonsense- and frameshift-mutated alleles were
eliminated by nonsense-mediated decay (NMD; Figure 2b).
Consistent with nonsense-mediated decay being the mechanism
by which nonsense- and frameshift-mutated alleles are degraded,
all but two of these mutations obeyed the rule for termination-
codon position30,31 in which the premature termination codon
must be 455 nt upstream of the last exon-exon junction to result
in NMD (Supplementary Table 1). These data indicate that the
majority of CTCF mutations in endometrial carcinoma result in
inactivation of one allele.
CTCF haploinsufficiency occurs in serous endometrial carcinoma
We next determined if somatic copy number alterations in CTCF
occurred in endometrial carcinoma (as estimated by GISTIC from
within the TCGA portal). Loss in CTCF copy number occurred in
7.0% of endometrioid and 65.5% of serous subtype tumours,
indicating that CTCF genetic deletion was more common in poorer
prognosis serous subtype tumours (Fisher’s exact test, Po0.001;
Figure 2c). When samples with somatic CTCF mutations were
excluded, relative linear copy number values for CTCF correlated
with CTCF mRNA expression (ρ= 0.384, Spearman’s log-rank
correlation). Furthermore, samples with somatic CTCF deletion
expressed significantly less CTCF mRNA (Po0.001, Mann–Whitney
test; Figure 2d). CTCF copy number gain was observed in only a
single serous carcinoma sample. Survival analysis restricted to
patients with serous tumours showed that tumours with CTCF
copy number loss resulted in reduced overall survival compared to
CTCF diploid tumours (Figure 2e and Supplementary Figure 1).
These indicate that genetic deletion of CTCF, potentially in concert
with other deleted genes on chromosome 16q, results in poorer
patient outcomes.
Loss- and gain-of-function CTCF mutations are observed in
endometrial cancer
We incorporated three recurrent CTCF missense mutations found
in endometrial carcinoma,5 K365T, R377H and P378L (Figures 1a
and c) into lentiviral expression constructs containing HA-tagged
wild-type (WT) CTCF. We functionally characterised WT and
mutant CTCF in CTCF-haploinsufficient Ishikawa cells. All three
mutants of CTCF were indistinguishable from WT in their nuclear
localisation (Figure 3a) and were expressed at similar levels (Figure
3b). We next performed established cellular assays to measure the
activity of CTCF including proliferation and colony-forming
assays.15,17 Both R377H and P378L abrogated the growth
inhibitory effects of WT CTCF (Po0.05) such that they were
indistinguishable from control eGFP vector (Figure 3c). The K365T
mutation did not alter the anti-poliferative effect of WT CTCF.
Furthermore, R377H and P378L showed loss-of-function by
abrogating the inhibition of clonogenicity of WT CTCF (Po0.01
and Po0.001 respectively), while K365T again behaved similarly
to WT CTCF (Figure 3d). We explored the effect of each mutation
on CTCF function further by examining UV-induced apoptosis in
Ishikawa cells. WT CTCF has a protective effect compared to
control (Po0.01; Figure 3e) as expected.17 The K365T mutation
enhanced this pro-survival effect (Po0.001), suggesting a gain-of-
function in CTCF while neither R377H nor P378L showed any
increase in survival compared to control.
CTCF knockdown promotes loss of endometrial cell line polarity in
3D culture
As the majority of CTCF mutations identified in endometrial
carcinoma effectively result in inactivation of one CTCF allele, we
modelled this using inducible shRNA knockdown of CTCF. In
shCTCF KLE cells we reduced CTCF expression by about half
(Figure 4a). However, we did not detect any significant change in
cell proliferation after CTCF knockdown (Figure 4b). As with CTCF
overexpression studies, we observed a decrease of colony
CTCF genetic alterations
AD Marshall et al
4101
Oncogene (2017) 4100 – 4110
formation with shRNA knockdown of CTCF (Figure 4c). This is
consistent with preliminary CRISPR genome editing studies
performed in our laboratory (data not shown). However, knock-
down of CTCF did not have any effect on KLE cell survival in
response to UV treatment (Figure 4d). These data indicate that
there is not a simple linear relationship between CTCF expression
level and cell characteristics such as cell growth, colony formation
and protection from apoptosis. Colony formation in particular
shows that neither over- nor underexpression of CTCF is optimal
for maximal colony formation.
Endometrial cancer cell lines such as KLE are derived from
glandular epithelium, and as such, can be induced in vitro to grow
spheroids reminiscent of endometrial glands.32 These endometrial
spheroids display basal/apical polarity when stained for F-actin, a
marker of apical polarity based on phalloidin staining, and the
apical tight junction protein ZO-1.33 Using this staining technique
we found that spheroids generated from KLE cells after CTCF
knockdown had a reduced proportion of spheroids showing
apical/central F-actin and ZO-1 staining compared to control
cells (Figures 4e and f). This shows that reduced CTCF gene
expression disrupts endometrial cancer cell polarity, a morpholo-
gical change characteristic of epithelial cancer development.34
There was no consistent change observed with CTCF knockdown
compared to the three relevant controls in spheroid area, spheroid
number, ZO-1 staining intensity or F-actin staining intensity
(Supplementary Figure 2).
CTCF knockdown alters KLE gene expression
To identify the impact of CTCF knockdown on global gene
expression in KLE cells we performed gene expression micro-
arrays. We identified a total of 1744 genes that were differentially
expressed in KLE cells after 8 days of induction of CTCF
knockdown (Figure 5a and Supplementary Table 3). Gene
ontology analysis of this data set revealed significant enrichment
for the following terms: Process: regulation of retinoic acid
receptor signaling pathway; Function: identical protein binding,
protein homodimerisation activity, protein binding, and protein
dimerisation activity; Component: intracellular part, cytoplasmic
part (Figure 5b).
CTCF genetic deletion is associated with relapse or metastasis, and
clear cell histology
We examined a small independent cohort of 23 primary
endometrial malignancies as well as 8 primary tumour samples
which developed local relapse and 7 primary tumour samples that
presented or later developed metastasis. DNA isolated from FFPE
samples was analysed using a custom Nanostring nCounter copy
number variation panel of cancer-associated genes across the
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Figure 1. CTCF mutations in human endometrial carcinoma. (a) Summary of all CTCF inactivating (nonsense and frameshift; red) and missense
(green) mutations identified in primary human endometrial carcinomas5–7 (round lollipops, above). Novel CTCF mutations identified in
endometrial cancer cell lines (square lollipops, below). The location of ZFs (black) and nuclear localisation signal (NLS; blue). Recurrent
mutations K365T, R377H and P378L functionally characterised in this study are indicated. (b) Heatmap showing the frequency of missense
mutations in different ZF domains of CTCF ranging from 0 (white) to 15 (dark pink) residues, **Po0.01 Fisher’s exact test compared to
expected. (c) Representative electropherograms of somatic mutations in endometrial cancer cell lines: R342H, G19*, T204fs*26, R278C. (d) The
frequency of CTCF missense mutations found in endometrial carcinoma superimposed on a C2H2 ZF schematic. Note: some ZFs contain only
3 residues juxtaposed between conserved C-terminal histidine residues.
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long arm of chromosome 16 (16q) with a particular focus on
16q22.1 where CTCF is located (Figure 6). Within the 23 primary
samples only a single grade 2 endometrioid carcinoma showed
CTCF deletion. Among the 8 tumours that relapsed, 3 showed
CTCF deletion including a grade 2 endometrioid tumour and two
clear cell carcinomas. Among tumours that developed metastases,
two of seven showed CTCF deletion including a mixed grade 3
endometrioid/clear cell tumour and a grade 2 endometrioid
tumour. Collectively CTCF was more likely to be deleted in
endometrial tumours that developed relapse or metastasis than
primary malignancies (P= 0.0268, Fisher’s exact test). Moreover,
two of three relapsed tumours exhibited clear cell histology and
one of two metastatic tumours displayed mixed endometrioid/
clear cell histology. This indicates a possible association between
the presence of clear cell histology and CTCF deletion (P= 0.0259,
Fisher’s exact test), which warrants further investigation in a more
extensive cohort. We found no evidence that CTCF deletion
occurred specifically in relapsed or metastatic tumours using
matched primary and relapse or metastatic samples (four each,
Supplementary figure 3).
DISCUSSION
We and others5–7 have shown that CTCF is mutated in about one
quarter of endometrioid adenocarcinomas. The majority of these
somatic CTCF mutations are inactivating mutations resulting from
nonsense, frameshift or splice site mutations, which we show are
rarely expressed due to nonsense-mediated decay35 of mutant
transcripts, consistent with other reports.7 The missense mutations
which have been identified occurred predominantly in the 11-ZF
DNA binding domain of CTCF. A number of CTCF ZF mutations
previously identified in isolated cancers were shown to inhibit
CTCF binding to specific DNA binding sites such as CMYC and
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Figure 2. CTCF is mutated in endometrioid carcinoma and deleted in serous carcinoma. Analysis of mutation and copy number variation from
published data.5 (a) Proportion of endometrioid (Endo, n= 172) and serous samples (n= 60) with mutations in CTCF; ***Po0.001 Fisher’s exact
test. (b) Proportion of missense (n= 16) or inactivating (nonsense and frameshift; n= 25) mutations in all reads obtained by DNA Seq and RNA
Seq spanning the mutation site in samples; ns not significant, **Po0.01, ***Po0.001, Mann–Whitney non-parametric test. (c) CTCF gene copy
number analysis of endometrioid (n= 172) and serous (n= 60) samples using GISTIC; ***Po0.001 Fisher’s exact test. (d) CTCF gene expression
in non-CTCF mutant endometrial and serous samples categorised for CTCF copy number using GISTIC (Loss n= 51, Diploid n= 128 and Gain
n= 1); ***Po0.001 Fisher’s exact test. (e) Survival analysis of serous endometrial cancer samples with (n= 34) or without (n= 17) CTCF genetic
deletion; P= 0.0156, log-rank (Mantel Cox) test.
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the β-globin and APPβ regulatory regions was unaffected.10 In
endometrial carcinoma these missense mutations appear to
cluster within ZFs 4–5 of CTCF. ZFs 4-7 are responsible for binding
to the 20 bp core binding motif of CTCF which constitutes ~ 80%
of all CTCF target sites across the genome.36
Recurrent CTCF missense mutations in endometrial cancer
occur within inter-ZF regions (R377H and P378L), and within
conserved residues critical for zinc co-ordination or residues that
directly contact the minor groove of DNA (K365T). R377H and
P378L are loss-of-function mutations which abrogate the tumour
suppressive effects of CTCF. These inter-ZF mutations may alter
the conserved DNA binding domain structure and prevent normal
CTCF function. Conversely, K365T did not disrupt the tumour
suppressive effect of CTCF on cellular growth but enhanced
CTCF’s response to UV-induced apoptosis indicating a pro-survival
gain-of-function. As this residue directly contacts DNA, this
mutation may alter DNA binding specificity. The exact nature or
consequences of this altered binding has yet to be determined.
Despite our demonstration of a gain-of-function mutation in
CTCF, the majority of CTCF mutations in endometrial cancer result
in loss-of-function. We and others have found that the mechanism
of CTCF gene inactivation differs between cancer subtypes.
Microsatellite instability (MSI)-positive endometrioid tumours are
prone to strand slippage mutations in CTCF resulting in the
recurrent T204fs*18 and T204fs*26 mutations.7 We found that
CTCF is genetically deleted in a further 22% of all endometrial
carcinomas, and that the highest rates of CTCF genetic deletion
occur in endometrial serous carcinomas (65.5%). Consequently,
these result in a significant reduction in CTCF gene expression,
indicating that haploinsufficient deletion of CTCF may be
important in endometrial carcinoma pathogenesis and/or pro-
gression. In addition, other genes within Chr16q are often
concurrently deleted with CTCF. The haploinsufficienct loss of
these additional genes may synergise with CTCF haploinsuffi-
ciency in promoting more aggressive behaviour in endometrial
carcinomas. Thus the mechanism of CTCF inactivation could
contribute to tumour subtype and prognosis.
CTCF has previously been suggested as a target of 16q22.1
deletions observed in various cancer types.6,9,37,38 CTCF is located
within the minimally deleted region of 16q22.1,37 however other
candidate genes such as E-cadherin (CDH1) and ZFHX3 have also
been suggested.6,38 E-cadherin is required for normal develop-
ment and function of the endometrium,39 while loss of E-cadherin
staining is associated with endometrial carcinoma development
and poor prognosis.40,41 Likewise, somatic ZFHX3 mutations occur
in about 20% of endometrial cancers and are associated with poor
patient outcomes.6 We have determined that haploinsufficient
deletions of 16q, which usually contain CTCF, are associated with
serous, and now potentially clear cell histology and poorer
prognosis. This provides the first evidence that CTCF inactivation
in conjunction with inactivation of CDH1 and/or ZFHX3 and/or
other candidate genes on 16q contributes to the development of
poorer prognosis tumour subtypes. Any additive or synergistic
effect between CTCF haploinsufficiency and that of other
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Figure 3. CTCF mutations alter normal CTCF function. (a) Subcellular localisation and (b) Western blot expression level of HA-tagged wild-type
(WT), K365T, R377H and P378L CTCF in Ishikawa cells as detected by the anti-HA antibody; scale bar= 10 μm; inset shows DAPI staining of
nuclei. Functional analysis of Ishikawa cells expressing CTCF WT, K365T, R377H and P378L, or control eGFP vector: MTT proliferation assay
(c); colony formation assay (d); and apoptosis assay following recovery from UV exposure (e); * indicates a significant difference from control;
‡ indicates a significant difference from WT CTCF; * or ‡Po0.05, ** or ‡‡Po0.01, *** or ‡‡‡Po0.001 Student’s T-test. Data are mean± s.e.m of
3–4 independent experiments.
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CTCF has been established as a tumour suppressor gene due to
its ability to suppress cancer cell growth.15,17,25 Along with PTEN,
TP53, PIK3CA, CTNNB1 and ARID1A, CTCF has been classified as a
significantly mutated gene in endometrial cancer.8 Ctcf haploin-
sufficient mice, which are tumour prone, also develop endometrial
cancers.25 These observations firmly implicate CTCF mutation and
haploinsufficiency in endometrial carcinoma pathogenesis. How-
ever the cellular consequences of CTCF mutation and haploinsuf-
ficiency had not been investigated. Here we show that at least one
recurrent mutation in CTCF, K365T, exhibits a pro-survival gain-of-
function phenotype which could contribute to tumourigenesis. To
date, this gain-of-function mutation, K365T has been identified in
two cases of endometrioid adenocarcinoma5 and one serous
carcinoma case.26 This K365T mutation is the only CTCF mutation
to be identified in a worse prognosis serous subtype tumour.
Conversely the majority of endometrial cancer-associated genetic
changes to CTCF result in inactivation of one allele of CTCF leading
to haploinsufficiency. Here we show that these can deregulate
endometrial cell polarity, a phenotype which is associated with
malignancy. Thus, loss-of-function missense mutations, inactivat-
ing mutations and genetic copy number loss are different
mechanisms which achieve reduced CTCF gene dosage and/or
expression and/or CTCF protein activity. To date, no homozygous
deletion resulting in complete inactivation of CTCF has been
reported in tumours. A single case has been reported showing
homozygous deletion of CTCF exon 36 which encodes the entirety
of the N-terminus of CTCF. RNA sequencing was not performed to
determine if alternative transcripts of CTCF were expressed. CTCF
is absolutely required for development as Ctcf null mouse



































































































































Figure 4. CTCF knockdown alters clonogenicity and endometrial cancer spheroid polarity. (a) Immunoblot of KLE cells transduced with
inducible shControl or shCTCF shRNA vectors in KLE cells with or without doxycycline (Dox) induction. Densitometric ratio of CTCF expression
compared to non-Dox induced samples is shown. Functional analysis of KLE cells expressing either shControl or shCTCF with or without Dox
induction: MTT assay (b); colony formation assay (c); and apoptosis assay following recovery from UV insult (d). (e) Maximum intensity
projections of confocal images of representative KLE endometrial spheroids expressing shControl or shCTCF stained with rabbit anti-ZO-1
(green), F-actin (rhodamine phalloidin, red) and DAPI (blue); scale bar= 10 μm. (f) Quantitation of spheroids polarisation; ns not significant,
**Po0.01 Student’s t-test. Data are mean± s.e.m of 3–4 independent experiments.
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complete loss of CTCF in tumours would be detrimental to cell
viability and tumourigenesis, similar to when enforced deletion of
both alleles of DICER1, a known haploinsufficient tumour
suppressor gene, leads to inhibition of tumourigenesis.43
CTCF haploinsufficiency also destabilises DNA methylation at
epigenetically variable CpGs in normal tissues.25 It is not clear
what specific effects this global epigenetic instability would
have on endometrioid cells, but such deregulation may
accelerate carcinogenesis, and is indeed recognised as an
enabling factor in cancer.44 Paradoxically we show that knock-
down of CTCF can have both pro-tumourigenic (deregulation of
cellular polarity) and anti-tumourigenic (inhibition of clonogeni-
city) activities. Also, either CTCF overexpression or knockdown
inhibit colony formation in endometrial cancer cells. This
indicates that CTCF must be tightly regulated to ensure normal
cell function.
The endometrium of a reproductive human female (from puberty
to menopause, excluding pregnancy) is a dynamic tissue under-
going monthly cycles of proliferation, secretion and menstruation.
This cycling is accompanied by dramatic morphological changes in
the endometrial glands. However, despite these changes, the
glandular epithelial cells maintain normal apical-basal polarity
through specific subcellular expression of polarity proteins.45 Loss
of cellular polarity allows cells to override normal contact inhibition
signals and is thus a hallmark of cancer.44 This is consistent with the
finding of Kemp et al.25 who showed that CTCF haploinsufficiency
did not alter the proliferation of MEFs under subconfluent
conditions but showed loss of contact inhibition at confluency.
CTCF knockdown in the KLE endometrial cancer cell line reduces
the proportion of endometrial cancer spheroids showing central
luminal staining of apical polarity markers. Loss of cellular
polarity is thought to be an early event in endometrial cancer
development, as it is evident in endometrial atypical hyperplasia
which progresses to malignant carcinoma in about a third of
patients.46,47 Moreover, loss of cellular polarity is an important
aspect of epithelial to mesenchymal transition (EMT) known to
be involved in tumour progression.48 Interestingly, in mice,
Ctcf+/− tumours exhibit increased aggressiveness, including
invasion, metastasis and mixed epithelial and mesenchymal
morphology.25 This is the first time that CTCF has been
implicated in the regulation of cellular polarity, and could
indicate an important role for CTCF haploinsufficiency in the
development of endometrial and other cancers.
Here we showed that knockdown of CTCF resulted in the
significant deregulation of gene expression in KLE cells. Using
gene process ontology analysis we found significant enrichment
for genes associated with the retinoic acid receptor signalling
pathway. Interestingly retinoic acid receptor signalling has been
associated with differentiation, decidualisation and cancer forma-
tion in the endometrium,49–51 and is also associated with the
regulation of glandular epithelium polarity.52 This may offer a
gene regulatory mechanism by which CTCF haploinsufficiency
contributes to endometrial cancer development.
In conclusion, we have shown that CTCF mutations and genetic
deletions predominantly result in loss-of-function and more rarely
pro-survival gain-of-function phenotypes. CTCF mutation is
restricted to the endometrioid subtype of endometrial carcinoma,
while genetic deletion of Ch16q including the CTCF locus, occurs
predominantly in worse prognosis subtypes including serous
carcinoma, and our preliminary studies indicate clear cell
carcinoma. Inactivation of one allele of CTCF (CTCF haploinsuffi-
ciency) effectively reduces the amount of functional CTCF in
endometrial cancer cells. CTCF knockdown to recapitulate
haploinsufficiency resulted in deregulation of endometrial cancer
spheroid polarity which likely contributes to endometrial cancer
development and progression. Tumours with CTCF haploinsuffi-
ciency can now be shown to exhibit four different hallmarks of
cancer: sustained proliferative signalling, resisting cell death,
evading growth suppressors and epigenetic disregulation of the
genome.44 Our study provides further evidence of CTCF’s role as a
haploinsufficient tumour suppressor gene. Future studies to
explore the global consequences of CTCF haploinsufficiency on
three-dimensional genomic architecture and the transcriptional
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Figure 5. Knockdown of CTCF results in gene deregulation in KLE cells.
(a) Heat map of significantly (adjusted P-value o0.05) differentially
expressed genes in shControl (+Dox) samples compared to shCTCF
(+Dox) samples. Gene names are provided in Supplementary Table 3.
(b) Gene ontology analysis of differentially expressed genes showing
terms enriched with P-valueo10−3 and an FDR Q-value of o0.1.
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MATERIALS AND METHODS
Cell culture
Ishikawa, HEC1A, HEC1B, RL95-2 and KLE endometrial cancer cell lines were a
kind gift from Associate Professor Deborah Marsh of the Kolling Institute,
Sydney. Prior to commencing this study, these cell lines were authenticated
by short tandem repeat profiling in 2014 (CellBank, Westmead, NSW,
Australia). All cells were cultured in DMEM:F12 medium (Life Technologies,
Carlsbad, CA, USA) containing 10% (v/v) FBS and penicillin-streptomycin
solution at 37 °C and 5% CO2 with or without 1 μg/ml doxycycline (Dox) as
indicated. We used established methods for 3D spheroid culture.32,33 Briefly,
96-well imaging plates (Beckton Dickinson, Franklin Lakes, NJ, USA) were
coated in Matrigel (Corning, Tewksbury, MA, USA) and allowed to harden.
KLE cells (5 × 103/well) were plated in DMEM:F12 medium containing
penicillin-streptomycin, 1 mM HEPES, 5 ng/ml EGF, 1:100 dilution of Insulin-
Transferrin-Selenium (ITS) supplement (Life Technologies) and 3% (v/v)
Matrigel for 10 days with media changes every 2–3 days with or without
1 μg/ml Dox.
CTCF Sequencing
Genomic DNA was extracted from Ishikawa, HEC1A, HEC1B, RL95-2 and KLE
endometrial cancer cell lines using the Purelink genomic DNA isolation kit
(Life Technologies). PCR amplicons spanning CTCF exons 3-11 including
splice sites were amplified with established primers17 using Phusion DNA
Polymerase (NEB, Ipswich, MA, USA). Each PCR product was Sanger
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Figure 6. CTCF genetic deletion is associated with relapse and metastasis, and clear cell histology. A custom Nanostring nCounter Copy
Number Variation (CNV) Code Set was designed to span cancer-associated genes in the long arm of chromosome 16 with particular focus on
genes within 16q22.1 containing the CTCF locus (average of three probes, indicated by red border). Chromosome band and gene name are
labelled above. An endometrial cancer cohort (n= 23, top), endometrial carcinomas (EC) which relapsed (n= 8, middle), and endometrial
carcinomas (EC) which metastasised (n= 7, bottom) were analysed. CNV counts were normalised to the average of seven normal or benign
endometrium samples which were all considered diploid and any variation depicted on the heatmap. Federation Internationale de
Gynecologie et d'Obstetrique (FIGO) tumour grading scores are shown. Endometrial cancer histologies included endometrioid (Endo), Serous
(Ser), Clear Cell (CC), Carcinosarcoma (CS) and Squamous Carcinoma (Squ). Where mixed histologies were seen multiple subtypes are listed.
The sites of local relapse or metastasis are listed, and if detected at diagnosis (at diag); (LN) lymph node.
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sequenced in forward and reverse directions. All mutations were
confirmed by cloning each PCR amplicon into pCR-Blunt-TOPO (Life
Technologies) and re-sequencing.
Generation of lentiviral expression
Point mutations (K365T, R377H and P378L) were introduced into pCCLtet
eGFP-2A-HA-hCTCF17 using splice overlap extension PCR. Sequences for
shRNAs targeting human CTCF (shCTCF; 5′-tcccCGAAAGCAGCATTCC
TATAttcaagagaTATAGGAATGCTGCTTTCGcttttttc-3′) or encoding an Arabi-
dopsis thaliana microRNA 159a (shControl; 5′-tcccTTTGGATTGAAGG
GAGCTCttcaagagaGAGCTCCCTTCAATCCAAActtttttc-3′) were cloned into
BbsI/XhoI sites in the Dox-inducible vector pFH1tUTG.53 Lentiviral super-
natants for each vector were produced by calcium phosphate transfection
of HEK293T cells using Tat-independent packaging plasmids as previously
described.17 Lentiviral particles were then concentrated by ultracentrifuga-
tion for 2 h at 20,000 rpm, 4 °C in a SW28 Beckman rotor. Viral pellets were
resuspended on ice in complete Dulbecco's Modified Eagle Medium
(DMEM) in 1% of the original volume. Cells were transduced with lentivirus
in the presence of Polybrene (8 μg/ml) by spinoculation for 1.5 h. The
transduction media on cells was then replaced with fresh media.
Approximately 48 h post transduction, GFP-positive cells were sorted on
a FACSAria IIu (Becton Dickinson, Franklin Lakes, NJ, USA) and either plated
immediately for cell biology assays (CTCF mutants) or cultured in the
absence of Dox (shCTCF) until experiments were performed.
Immunoblotting, immunofluorescence, imaging and quantitation
For Western blotting, cell lysates were electrophoresed on NuPAGE Novex
4-12% Bis Tris Protein Gels (Life Technologies) and transferred to
nitrocellulose membrane using the iBlot System (Life Technologies).
Membranes were blocked in either 5% (v/v) skim milk in phosphate
buffered saline 0.1% (v/v) Tween-20 (PBST) or 1% (w/v) polyethylene glycol
MW3350, 1% (w/v) polyvinylpyrrolidone, 0.3% (w/v) bovine serum albumin
in PBST for 1 h at room temperature then incubated with 1:1000 mouse
anti-HA (Covance, Princeton, NJ, USA), 1:1000 rabbit anti-CTCF15 or 1:1000
mouse anti-tubulin (Santa Cruz, Dallas, TX, USA) in blocking buffer. Blots
were washed three times each for five minutes in PBST. Membranes were
incubated with anti-mouse/rabbit HRP (1:5000) in blocking buffer for 1 h at
room temperature. Membranes were the treated with chemiluminescent
reagent and exposed on an Image Station 4000R Pro (Kodak, Rochester,
NY, USA). Densitometry analysis was performed using Image J software
(NIH, Bethesda, MD, USA).
Cells or spheroids were rinsed in PBS and fixed in 10% (v/v) neutral
buffered formalin (Fronine, Riverstone, NSW, Australia) for 10 min at room
temperature (RT). Samples were washed 3 times for 5 min in phosphate
buffered saline (PBS) and then permeabilised with 0.5% (v/v) Triton X-100
in PBS for 10 min at RT. Samples were then washed in PBS as above.
Samples were blocked in 20% (v/v) BlokHen (Aves Labs, Tigard, OR, USA) in
PBS, 0.02% (v/v) Triton X-100 for 30 min at room temperature and
incubated with primary antibodies as follows: mouse anti-HA (1:1,000;
Covance) or rabbit anti-ZO-1 (1:100; Cell Signaling, Boston, MA, USA) in
blocking buffer for 1.5 h at RT. Samples were then washed 3 times for
5 min in PBS 0.1% (v/v) Triton X-100. Secondary antibodies: anti-mouse
Alexa Fluor 594 (1:5,000; Life Technologies) or anti-rabbit Alexa Fluor 488
(1:5,000; Life Technologies) and rhodamine phalloidin to bind F-actin
(1:200, Life Technologies) were incubated in blocking buffer for 1 h at RT.
Samples were washed 3 times for 5 min in PBS 0.1% Triton X-100. For
spheroids the first wash contained 0.2 μg/ml DAPI (Life Technologies) to
counterstain nuclei. Cells were mounted in Prolong Gold plus DAPI (Life
Technologies), and spheroids were covered with PBS. Imaging of cells
was performed on the DeltaVision Personal Deconvolution Microscope
(GE Healthcare, Chicago, IL, USA) and images deconvolved using SoftWoRx
software (GE Healthcare). Imaging of spheroids for scoring was performed
on a BD pathway (Becton Dickinson) and representative images were taken
on a Confocal SP5 (Leica, Wetzlar, Germany). Spheroids were scored for
central staining of both F-Actin and ZO-1 by a researcher blinded to
sample identity. There were an average of 105± 6 (mean± s.e.m) spheroids
per image, one image per well, and duplicate wells for each experiment.
Four replicate experiments were analysed.
Cell biology assays
All cell biology assays were performed on GFP-positive cells as previously
described.17 Briefly, MTT cell proliferation assays were performed using
200-250 cells/well plated in a 96-well plate in triplicate and proliferation
was assessed at 0, 2, 4, 6 and 8 d by the addition of 3-(4,5-Dimethylthiazol-
2-yl)− 2,5-diphenyltetrazolium bromide (MTT, Merck, Kenilworth, NJ, USA)
overnight. The reaction was quenched with isopropanol/HCl and the
optical density at 570 and 630 nm measured using a POLARstar Omega
plate reader (BMG Labtech, Ortenberg, Germany). Clonogenicity assays
were performed using 1000 cells/10 cm dish in triplicate and incubated for
10-20 d. Cells were rinsed in PBS and fixed with ice-cold methanol, then
stained with Giemsa solution diluted 1:20 in H2O. The colonies were scored
by a researcher blinded to sample identity. For apoptosis experiments,
1 × 105 cells were plated in 24-well plates and incubated overnight. The
medium was replaced with PBS and cells were UV irradiated (Ishikawa
1000 μJ, KLE 4000 μJ) in a Stratalinker (Stratagene, San Diego, CA, USA).
After 18 h recovery, both adherent and non-adherent cells were stained for
flow cytometry using Annexin V-APC (Becton Dickinson) and DAPI (Sigma,
Croydon, UK). Viable cells were defined as those cells that were negative
for both stains.
Gene expression array analysis
Triplicate samples of KLE cells expressing either shControl or shCTCF
knockdown lentivectors were treated with doxycycline for 8 days prior to
isolation of RNA. Gene expression analysis was performed using the
GeneChIP PrimeView Human Gene Expression Array (Affymetrix, Santa
Clara, CA, USA). Analysis was performed using the Bioconductor packages
affy and limma. Array data were normalised using the Robust Multi-array
Average (RMA) approach. We applied an intensity based filter to remove
probe sets that were not expressed. Differentially expressed genes were
identified by fitting a linear model to the data and applying an empirical
Bayes smoothing to the standard errors. P-values were Benjamini-
Hochberg adjusted. Gene ontology analysis was performed using GOrilla
(http://cbl-gorilla.cs.technion.ac.il)54 using a background of expressed
genes, a P-value threshold of o10− 3, and FDR Q-value threshold of o0.1.
Genetic analysis of primary human samples
Archived formalin-fixed, paraffin-embedded (FFPE) primary human endo-
metrial cancer samples and associated clinical data (which was extracted
from patient case notes and the secure password-protected hospital
database) were deidentified and obtained from the Royal Prince Alfred
Hospital in accordance with Sydney Local Health District-approved human
ethics protocol (X12-0380). DNA from samples was isolated using the
QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. DNA concentrations were determined by
spectrophotometry (Nanodrop) and 500 ng of DNA was prepared for use
on a custom nCounter Copy Number Variation Panel (Nanostring, Seattle,
WA, USA) with probes measuring the copy number of cancer-associated
genes along the long arm of chromosome 16. Copy number values were
normalised to seven normal or benign endometrium FFPE samples isolated
from the same location which were considered diploid.
ABBREVIATIONS
CTCF, CCCTC-binding factor; Dox, Doxycycline; FBS, Fetal bovine serum;
FFPE, Formalin-fixed paraffin-embedded; HRP, Horseradish peroxidase;
SMG, Significantly mutated gene; WT, Wild type; ZF, Zinc finger.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ACKNOWLEDGEMENTS
Financial support was provided by Tour de Cure (Scott Canner Research Fellowship)
to CGB and for research grants to ADM, CGB and JEJR; Cancer Council NSW project
grants (RG14-09) to JEJR and CGB; (RG14-05) to JEJR; support grants from Cure The
Future Foundation and an anonymous foundation; National Institute of General
Medical Sciences Cell and Molecular Biology training grant (GM 007067) to RJ.
We thank the Centenary Institute Advanced Cytometry Facility for FACS and imaging.
The authors acknowledge the University of Sydney HPC service at The University of
Sydney for providing HPC, visualisation, database, and/or grid resources that have
contributed to the research results reported within this paper. URL: http://sydney.edu.
au/research_support/.
CTCF genetic alterations
AD Marshall et al
4108
Oncogene (2017) 4100 – 4110
AUTHOR CONTRIBUTIONS
CTCF gene sequencing: ADM, CGB, KC, YF and CM. Analysis of previously
published CTCF data in endometrial cancer: ADM, CGB, RJ, LD and EM.
Generation of lentiviral expression vectors: CGB, CM and PO. Immunofluores-
cence and imaging: ADM, KC and MV. Cell biology assays: ADM, CGB, KC, MV,
MB and PO. Analysis of independent endometrial cancer cohort: ADM, AR and
LA. Conception, Supervision and Experimental Design: ADM, CGB and JEJR.
Drafting of the article: ADM. Critical revision of manuscript: CGB and JEJR.
REFERENCES
1 Haidopoulos D, Simou M, Akrivos N, Rodolakis A, Vlachos G, Fotiou S et al. Risk
factors in women 40 years of age and younger with endometrial carcinoma. Acta
Obstet Gynecol Scand 2010; 89: 1326–1330.
2 Ukraintseva SV, Arbeev KG, Yashin AI. Epidemiology of hormone-associated
cancers as a reflection of age. Adv Exp Med Biol 2008; 630: 57–71.
3 Kurman RJ, Caracangiu ML, Herrington CS, Young RHE. World Health Organization
Classification of Tumours of Female Reproductive Organs., 4th edn, IARC: Lyon,
France, 2014, p 128.
4 Llaurado M, Ruiz A, Majem B, Ertekin T, Colas E, Pedrola N et al. Molecular bases of
endometrial cancer: new roles for new actors in the diagnosis and the therapy of
the disease. Mol Cell Endocrinol 2012; 358: 244–255.
5 Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H et al. Integrated
genomic characterization of endometrial carcinoma. Nature 2013; 497: 67–73.
6 Walker CJ, Miranda MA, O'Hern MJ, McElroy JP, Coombes KR, Bundschuh R et al.
Patterns of CTCF and ZFHX3 mutation and associated outcomes in
endometrial cancer. J Natl Cancer Inst 2015; 107: djv249.
7 Zighelboim I, Mutch DG, Knapp A, Ding L, Xie M, Cohn DE et al. High frequency
strand slippage mutations in CTCF in MSI-positive endometrial cancers. Hum
Mutat 2014; 35: 63–65.
8 Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C et al. Mutational
landscape and significance across 12 major cancer types. Nature 2013; 502:
333–339.
9 Aulmann S, Blaker H, Penzel R, Rieker RJ, Otto HF, Sinn HP. CTCF gene muta-
tions in invasive ductal breast cancer. Breast Cancer Res Treat 2003; 80:
347–352.
10 Filippova GN, Qi CF, Ulmer JE, Moore JM, Ward MD, Hu YJ et al. Tumor-associated
zinc finger mutations in the CTCF transcription factor selectively alters its DNA-
binding specificity. Cancer Res 2002; 62: 48–52.
11 Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA et al.
CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011; 471:
235–239.
12 Yoshida K, Toki T, Okuno Y, Kanezaki R, Shiraishi Y, Sato-Otsubo A et al. The
landscape of somatic mutations in Down syndrome-related myeloid disorders.
Nat Genet 2013; 45: 1293–1299.
13 Phillips JE, Corces VG. CTCF: master weaver of the genome. Cell 2009; 137:
1194–1211.
14 Marshall AD, Bailey CG, Rasko JE. CTCF and BORIS in genome regulation
and cancer. Curr Opin Genet Dev 2014; 24: 8–15.
15 Rasko JE, Klenova EM, Leon J, Filippova GN, Loukinov DI, Vatolin S et al. Cell
growth inhibition by the multifunctional multivalent zinc-finger factor CTCF.
Cancer Res 2001; 61: 6002–6007.
16 Li T, Lu L. Functional role of CCCTC binding factor (CTCF) in stress-induced
apoptosis. Exp Cell Res 2007; 313: 3057–3065.
17 Tiffen JC, Bailey CG, Marshall AD, Metierre C, Feng Y, Wang Q et al. The cancer-
testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and
neoplastic cells. Int J Cancer 2013; 133: 1603–1613.
18 Lobanenkov VV, Nicolas RH, Adler VV, Paterson H, Klenova EM, Polotskaja AV et al.
A novel sequence-specific DNA binding protein which interacts with three reg-
ularly spaced direct repeats of the CCCTC-motif in the 5'-flanking sequence of the
chicken c-myc gene. Oncogene 1990; 5: 1743–1753.
19 Watanabe N, Haruta M, Soejima H, Fukushi D, Yokomori K, Nakadate H et al.
Duplication of the paternal IGF2 allele in trisomy 11 and elevated expression
levels of IGF2 mRNA in congenital mesoblastic nephroma of the cellular or
mixed type. Genes Chromosomes Cancer 2007; 46: 929–935.
20 Soto-Reyes E, Recillas-Targa F. Epigenetic regulation of the human p53 gene
promoter by the CTCF transcription factor in transformed cell lines. Oncogene
2010; 29: 2217–2227.
21 Renaud S, Loukinov D, Bosman FT, Lobanenkov V, Benhattar J. CTCF binds the
proximal exonic region of hTERT and inhibits its transcription. Nucleic Acids Res
2005; 33: 6850–6860.
22 Hirosue A, Ishihara K, Tokunaga K, Watanabe T, Saitoh N, Nakamoto M et al.
Quantitative assessment of higher-order chromatin structure of the INK4/ARF
locus in human senescent cells. Aging Cell 2012; 11: 553–556.
23 Lai AY, Fatemi M, Dhasarathy A, Malone C, Sobol SE, Geigerman C et al. DNA
methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell
lymphomas. J Exp Med 2010; 207: 1939–1950.
24 Witcher M, Emerson BM. Epigenetic silencing of the p16(INK4a) tumor suppressor
is associated with loss of CTCF binding and a chromatin boundary. Mol Cell 2009;
34: 271–284.
25 Kemp CJ, Moore JM, Moser R, Bernard B, Teater M, Smith LE et al. CTCF hap-
loinsufficiency destabilizes DNA methylation and predisposes to cancer. Cell Rep
2014; 7: 1020–1029.
26 Le Gallo M, O'Hara AJ, Rudd ML, Urick ME, Hansen NF, O'Neil NJ et al. Exome
sequencing of serous endometrial tumors identifies recurrent somatic mutations
in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet 2012; 44:
1310–1315.
27 Kuramoto H, Tamura S, Notake Y. Establishment of a cell line of
human endometrial adenocarcinoma in vitro. Am J Obstet Gynecol 1972; 114:
1012–1019.
28 Richardson GS, Dickersin GR, Atkins L, MacLaughlin DT, Raam S, Merk LP et al. KLE:
a cell line with defective estrogen receptor derived from undifferentiated
endometrial cancer. Gynecol Oncol 1984; 17: 213–230.
29 Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S et al. The
Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug
sensitivity. Nature 2012; 483: 603–607.
30 Jung H, Lee D, Lee J, Park D, Kim YJ, Park WY et al. Intron retention is a
widespread mechanism of tumor-suppressor inactivation. Nat Genet 2015; 47:
1242–1248.
31 Nagy E, Maquat LE. A rule for termination-codon position within intron-containing
genes: when nonsense affects RNA abundance. Trends Biochem Sci 1998; 23:
198–199.
32 Marshall AD, van Geldermalsen M, Otte NJ, Anderson LA, Lum T, Vellozzi MA et al.
LAT1 is a putative therapeutic target in endometrioid endometrial carcinoma. Int J
Cancer 2016; 139: 2529–2539.
33 Eritja N, Llobet D, Domingo M, Santacana M, Yeramian A, Matias-Guiu X et al.
A novel three-dimensional culture system of polarized epithelial cells to study
endometrial carcinogenesis. Am J Pathol 2010; 176: 2722–2731.
34 Royer C, Lu X. Epithelial cell polarity: a major gatekeeper against cancer? Cell
Death Differ 2011; 18: 1470–1477.
35 Wong JJ, Ritchie W, Ebner OA, Selbach M, Wong JW, Huang Y et al. Orchestrated
intron retention regulates normal granulocyte differentiation. Cell 2013; 154:
583–595.
36 Nakahashi H, Kwon KR, Resch W, Vian L, Dose M, Stavreva D et al. A Genome-
wide Map of CTCF Multivalency Redefines the CTCF Code. Cell Rep 2013; 3:
1678–1689.
37 Filippova GN, Lindblom A, Meincke LJ, Klenova EM, Neiman PE, Collins SJ et al.
A widely expressed transcription factor with multiple DNA sequence specificity,
CTCF, is localized at chromosome segment 16q22.1 within one of the smallest
regions of overlap for common deletions in breast and prostate cancers. Genes
Chromosomes Cancer 1998; 22: 26–36.
38 Rakha EA, Armour JA, Pinder SE, Paish CE, Ellis IO. High-resolution analysis of
16q22.1 in breast carcinoma using DNA amplifiable probes (multiplex amplifiable
probe hybridization technique) and immunohistochemistry. Int J Cancer 2005;
114: 720–729.
39 Reardon SN, King ML, MacLean JA 2nd, Mann JL, DeMayo FJ, Lydon JP et al. CDH1
is essential for endometrial differentiation, gland development, and adult func-
tion in the mouse uterus. Biol Reprod 2012; 86: 141.
40 Carico E, Atlante M, Giarnieri E, Raffa S, Bucci B, Giovagnoli MR et al. E-cadherin
and alpha-catenin expression in normal, hyperplastic and neoplastic endome-
trium. Anticancer Res 2010; 30: 4993–4997.
41 Gonzalez-Rodilla I, Aller L, Llorca J, Munoz AB, Verna V, Estevez J et al. The
E-Cadherin expression vs. tumor cell proliferation paradox in endometrial cancer.
Anticancer Res 2013; 33: 5091–5095.
42 Moore JM, Rabaia NA, Smith LE, Fagerlie S, Gurley K, Loukinov D et al. Loss of
maternal CTCF is associated with peri-implantation lethality of Ctcf null embryos.
PLoS One 2012; 7: e34915.
43 Kumar MS, Pester RE, Chen CY, Lane K, Chin C, Lu J et al. Dicer1 functions as a
haploinsufficient tumor suppressor. Genes Dev 2009; 23: 2700–2704.
44 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;
144: 646–674.
45 Jiménez-Ayala M, J-AP B. Cytology of the normal endometrium – cycling and
postmenopausal. Endometrial Adenocarcinoma: Prevention and Early Diagnosis.
Karger: Basel, Switzerland, 2008; pp 32–39.
46 Allison KH, Reed SD, Voigt LF, Jordan CD, Newton KM, Garcia RL. Diagnosing
endometrial hyperplasia: why is it so difficult to agree? Am J Surg Pathol 2008; 32:
691–698.
47 Lacey Jr JV, Chia VM. Endometrial hyperplasia and the risk of progression to
carcinoma. Maturitas 2009; 63: 39–44.
CTCF genetic alterations
AD Marshall et al
4109
Oncogene (2017) 4100 – 4110
48 Moreno-Bueno G, Portillo F, Cano A. Transcriptional regulation of cell polarity in
EMT and cancer. Oncogene 2008; 27: 6958–6969.
49 Brar AK, Kessler CA, Meyer AJ, Cedars MI, Jikihara H. Retinoic acid suppresses in-
vitro decidualization of human endometrial stromal cells. Mol Hum Reprod 1996;
2: 185–193.
50 Cheng YH, Utsunomiya H, Pavone ME, Yin P, Bulun SE. Retinoic acid inhibits
endometrial cancer cell growth via multiple genomic mechanisms. J Mol Endo-
crinol 2011; 46: 139–153.
51 Li R, Saito T, Tanaka R, Satohisa S, Adachi K, Horie M et al. Hypermethylation in
promoter region of retinoic acid receptor-beta gene and immunohistochemical
findings on retinoic acid receptors in carcinogenesis of endometrium. Cancer Lett
2005; 219: 33–40.
52 Seewaldt VL, Caldwell LE, Johnson BS, Swisshelm K, Collins SJ, Tsai S. Inhibition of
retinoic acid receptor function in normal human mammary epithelial cells results
in increased cellular proliferation and inhibits the formation of a polarized
epithelium in vitro. Exp Cell Res 1997; 236: 16–28.
53 Herold MJ, van den Brandt J, Seibler J, Reichardt HM. Inducible and reversible
gene silencing by stable integration of an shRNA-encoding lentivirus in
transgenic rats. Proc Natl Acad Sci USA 2008; 105: 18507–18512.
54 Eden E, Navon R, Steinfeld I, Lipson D, Yakhini Z. GOrilla: a tool for discovery and
visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 2009; 10: 48.
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative Commons
license, users will need to obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://creativecommons.org/licenses/
by/4.0/
© The Author(s) 2017
Supplementary Information accompanies this paper on the Oncogene website (http://www.nature.com/onc)
CTCF genetic alterations
AD Marshall et al
4110
Oncogene (2017) 4100 – 4110
